These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24258833)

  • 1. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ; Jones AM; Webb AK; Horsley AR
    Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
    Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
    Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of sweat chloride and percent predicted FEV
    Fidler MC; Beusmans J; Panorchan P; Van Goor F
    J Cyst Fibros; 2017 Jan; 16(1):41-44. PubMed ID: 27773592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
    Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
    Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.
    McGarry ME; Nielson DW
    Chest; 2013 Oct; 144(4):e1-e4. PubMed ID: 24081349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
    Konstan MW; Plant BJ; Elborn JS; Rodriguez S; Munck A; Ahrens R; Johnson C
    Pediatr Pulmonol; 2015 May; 50(5):447-55. PubMed ID: 25755212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
    Secunda KE; Guimbellot JS; Jovanovic B; Heltshe SL; Sagel SD; Rowe SM; Jain M
    Am J Respir Crit Care Med; 2020 Apr; 201(8):996-998. PubMed ID: 31841644
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.
    Vermeulen F; Le Camus C; Davies JC; Bilton D; Milenković D; De Boeck K
    J Cyst Fibros; 2017 Jan; 16(1):36-40. PubMed ID: 26996268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).
    Baker E; Harris WT; Guimbellot JS; Bliton K; Rowe SM; Raju SV; Oates GR
    J Cyst Fibros; 2024 Sep; 23(5):959-966. PubMed ID: 39033068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
    Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.